SuperNOVA summer camp: High school students get hands-on experience solving climate problems
Jarman Ley, the program coordinator of SuperNOVA, said 25 students took part in the program focused on ocean technologies, engineering, and artificial intelligence.
'We started this program to get high school students excited and interested in the climate and how the ocean relates to that,' said Ley.
'They all developed programs for their own sensors and then drove them into the harbour to see the difference between historical harbour data and current harbour data.'
SuperNOVA
Students participating in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles into the Halifax Harbour Friday, July 25, 2025. (Paul DeWitt/CTV Atlantic)
The students are testing for oxygen, solidity, and the acidity of the water, said Ley.
'They are specifically doing dissolved oxygen to see if fish have enough oxygen to breathe. They are doing the solidity because as climate changes or temperature changes you can have saltier waters, which is inhospitable to plants. They are doing the acidity of the water, the oxygen reduction potential, which is essentially how the ocean cleans itself.'
Ley said the program teaches skills the students can take into their university careers.
'It's been a really interesting way to take all of the knowledge that we've learned and wrap it into one project that we can test and see the results of,' said student Finnegan Jafmann.
SuperNOVA
Students participating in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles into the Halifax Harbour Friday, July 25, 2025. (Paul DeWitt/CTV Atlantic)
'A lot of the people here are probably going to use this as really good experience because we got to go to a lot of places. We got to tour multiple parts of the Dal building and the engineering section, and we got to talk to a lot of people about their projects,' said student Emily Whidden. 'For me, it was a lot of interesting information, but for the people who are planning to go into these fields or even come to Dal, it was probably a really good foot in the door.'
From 2023 to date, Dalhousie University said SuperNOVA has reached more than 27,500 youth through this not-for-profit initiative.
'Young people are the lifeblood of the future. So, we really believe if we start to encourage them now, that they'll be that much more advanced when they get to university and potentially study it and develop the next generation of innovation,' said Ley.
According to Dalhousie University, SuperNOVA summer camps introduce participants to STEM concepts, careers and mentors through 'fun experiments and innovative hands-on activities.'
For more Nova Scotia news, visit our dedicated provincial page
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
4 hours ago
- National Post
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Article content – Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – Article content – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – Article content Article content – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – Article content – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – Article content SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Article content Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. Article content 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition.' Article content Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys ® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. Article content 'Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis,' said Matt Sause, CEO of Roche Diagnostics. 'Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families.' Article content Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Article content Pharmaceuticals Article content In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. Article content New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. Article content These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Article content Diagnostics Article content Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Article content Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys ® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys ® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Article content Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm – 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm – 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm – 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm – 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am – 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley Article content About trontinemab Article content Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. Article content The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. Article content About Roche in Alzheimer's Disease Article content With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. Article content About Genentech in Neuroscience Article content Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Article content Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. Article content Article content Article content Article content Article content
CTV News
19 hours ago
- CTV News
SuperNOVA summer camp: High school students get hands-on experience solving climate problems
High school students in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles to the test in the Halifax Harbour. Jarman Ley, the program coordinator of SuperNOVA, said 25 students took part in the program focused on ocean technologies, engineering, and artificial intelligence. 'We started this program to get high school students excited and interested in the climate and how the ocean relates to that,' said Ley. 'They all developed programs for their own sensors and then drove them into the harbour to see the difference between historical harbour data and current harbour data.' SuperNOVA Students participating in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles into the Halifax Harbour Friday, July 25, 2025. (Paul DeWitt/CTV Atlantic) The students are testing for oxygen, solidity, and the acidity of the water, said Ley. 'They are specifically doing dissolved oxygen to see if fish have enough oxygen to breathe. They are doing the solidity because as climate changes or temperature changes you can have saltier waters, which is inhospitable to plants. They are doing the acidity of the water, the oxygen reduction potential, which is essentially how the ocean cleans itself.' Ley said the program teaches skills the students can take into their university careers. 'It's been a really interesting way to take all of the knowledge that we've learned and wrap it into one project that we can test and see the results of,' said student Finnegan Jafmann. SuperNOVA Students participating in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles into the Halifax Harbour Friday, July 25, 2025. (Paul DeWitt/CTV Atlantic) 'A lot of the people here are probably going to use this as really good experience because we got to go to a lot of places. We got to tour multiple parts of the Dal building and the engineering section, and we got to talk to a lot of people about their projects,' said student Emily Whidden. 'For me, it was a lot of interesting information, but for the people who are planning to go into these fields or even come to Dal, it was probably a really good foot in the door.' From 2023 to date, Dalhousie University said SuperNOVA has reached more than 27,500 youth through this not-for-profit initiative. 'Young people are the lifeblood of the future. So, we really believe if we start to encourage them now, that they'll be that much more advanced when they get to university and potentially study it and develop the next generation of innovation,' said Ley. According to Dalhousie University, SuperNOVA summer camps introduce participants to STEM concepts, careers and mentors through 'fun experiments and innovative hands-on activities.' For more Nova Scotia news, visit our dedicated provincial page
CBC
a day ago
- CBC
Destined to be a boy mom? New study suggests baby's sex isn't always random
Ashley Clouthier says she hoped her first child would be a boy, so when he was, she was ecstatic. Clouthier, 39, of Almonte, Ont., grew up with an older brother, and wanted the same experience for the large family she was planning with her husband. And when their next child was also a boy, well, even better. Best buds close in age, she thought, and two big brothers for their brood of future children. But then their third child was a boy. And their fourth. Today, Clouthier's boys are ages 13, 12, 10 and four — and she says she's not planning to have any more children. But if she did? "I'm sure it would be a boy," she said with a laugh. There just might be some truth to that, according to a new study that suggests a child's sex at birth might not be entirely random. The study, published July 18 in the journal Science Advances, examined the maternal and genetic factors that influence the sex of offspring after several of the co-authors observed examples of friends, colleagues and family members who had produced either all boys or all girls, which, they say, raised questions about chance. Researchers at the Harvard T.H. Chan School of Public Health examined a dataset of 58,007 U.S. women with two or more singleton live births and found that "each family may have a unique probability of male or female births," they wrote in the study. "The data suggested that there may be families that are more likely than not to have only girls, [and] families that are more likely than not to have only boys," Dr. Jorge Chavarro, a professor of nutrition and epidemiology and one of the authors of the study, told CBC News. 'A weighted coin' Specifically, mothers with three or more children were more likely to have either all boys or all girls, which challenges the traditional view that the probability is "random and independent," or that you have a 50-50 chance of having a boy or a girl each pregnancy, the authors wrote. They calculated that, in families with three boys, the probability of having another boy was 61 per cent, and in families with three girls, the probability of having another girl was 58 per cent. "Akin to flipping a weighted coin with roughly a 60-40 probability," Chavarro explained. The study suggests that there are subtle biological or genetic influences at play, rather than pure chance, which is what we know to be true of most things in life, said Dr. Sebastian Hobson, the head of labour and delivery at Mount Sinai hospital in Toronto and a maternal fetal medicine specialist. Hobson, who is also the chair of obstetrics for the Society of Obstetricians and Gynaecologists of Canada and who was not involved in the study, noted that the Harvard study is large and methodologically rigorous, but as with any study, the results should be interpreted with caution. The observed effects are small, he said, don't determine cause and effect, and the large population was predominantly white and U.S.-based, so can't be generalized globally. They also didn't gather any information about the biological fathers, he added. "Biology can nudge these probabilities slightly, but predicting a child's sex remains highly uncertain," Hobson said. "I think this is a great study, but it's not the be all and end all of sex determination." WATCH | Is gentle parenting too rough on parents? Why more parents are ditching the gentle approach 5 months ago 'Lose the birth lottery' Previous studies have found that parents are more likely to have a third child if their first two are the same sex, often in hopes the third child will be the opposite. And you only have to spend some time at school pickups, playgrounds and community pools to see that, well, it doesn't always work out that way. One recent study in the Journal of Behavioral and Experimental Economics refers to those who have three boys or three girls as parents who "lose the birth lottery." "If I got paid $1 for every time someone said, 'Are you going to try for a girl?' I'd be a millionaire," said Krystyna Recoskie, 48, also of Almonte, Ont., and a friend of Clouthier's. She has three boys, ages 15, 13 and 11. "For a while, it made me feel like I had failed. Like it was bad. How ridiculous is that?" she added. "I am blessed. I am complete." In the Harvard study, the researchers found that two-child families were actually more likely to be opposite sexes, or boy-girl, which they suggested implies that "couples are more inclined to stop reproducing when a balanced sex was reached." As for why some mothers were more likely to give birth to all-boys or all-girls, the authors suggested some women are at high risk of producing offspring of a specific sex due to factors affecting sperm survival. As well, procreation behaviour can be strongly influenced by the sex of previous children, they added. In addition, the authors found that older maternal age at first birth could be a risk factor for repeatedly giving birth to children of only one sex. This may be due to biological changes in the body, they said, like shorter follicular phase and lower vaginal pH. 'Four boys, poor you' Other studies have explored the idea of gender disappointment, or the feeling of sadness a parent may experience when their child's sex doesn't match with what they'd hoped for, and suggest it's more prevalent than we may think. "Gender disappointment in Western cultures is mostly related to the desire for 'gender balance' in the family — having a child of each gender to experience being a mother to sons as well as daughters," notes a 2023 study in the BJPsych Bulletin journal. Clouthier says she's never been disappointed about having four boys, and any negativity she experiences comes from other people. In a lot of ways, it's easier to have four kids all the same sex, she explained, between the hand-me-downs and gear they already have on hand. Birthday party themes can also overlap. And yes, it can get loud, and rough, and there are kid-sized holes in the drywall, but she notes her boys are also sweet, sensitive and cuddly. "I still get comments all time time, where people say, 'Four boys, poor you,'" Clouthier said. And I'll say, 'Yeah, lucky me!'"
